Menu
About us
Overview
Our story
How we create value
Our people
Our portfolio
Overview
Gene Therapy
Overview
Freeline
Gyroscope
SwanBio
Purespring
Cell Therapy
Overview
Autolus
Achilles Therapeutics
Quell
Resolution
Neogene Therapeutics
Small molecule
Overview
OMass therapeutics
Biologics
Overview
Anaveon
Previous portfolio companies
Overview
Nightstar
Blue Earth
News and insights
Investor centre
Overview
Share price centre
RNS and inside information
Results and presentations
Financial calendar
Document library
Corporate Governance
Shareholder information
Sustainability
Overview
The Syncona Foundation
Syncona's approach to charity
Syncona FY20: Martin Murphy discusses the outlook for Syncona
Back to News and insights
Share this page
Martin Murphy - CEO
Published 11 Jun 2020
Play
Share this page:
Facebook
Twitter
Linkedin
Follow us on:
